Valuation: Artelo Biosciences, Inc.

Market Cap 1.05M 938K 858K 783K 1.47M 98.35M 1.52M 10.34M 4.12M 52.48M 3.93M 3.84M 166M P/E 2024
-0.35x
P/E 2025 -0.1x
Enterprise Value 1.12M 1.01M 922K 841K 1.58M 106M 1.63M 11.11M 4.43M 56.39M 4.22M 4.13M 178M EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
99.89%
Yield 2024 *
-
Yield 2025 -
10-29 Artelo Biosciences Presents ART27.13 Data Demonstrating Potential To Treat Chemotherapy-Induced Neuropathic Pain At The IASP 2026 World Congress On Pain CI
10-07 Artelo Biosciences, Inc. Showcases Clinical Progress And Expanding Potential Of Its Novel FABP5 Inhibitor Platform At BIO-Europe 2026 CI
09-23 Artelo Biosciences, Inc. Files New Provisional Patent Application Covering Art27.13 for Obesity, Alone and in Combination with Glp-1 Receptor Agonists CI
09-16 Artelo Biosciences, Inc. Announces ART27.13 Achieves Weight Loss Comparable To Semaglutide And Doubles Weight Loss In Combination In Nonclinical Obesity Model CI
08-20 Artelo Biosciences Secures Notice Of Allowance In Japan For Patent Claims For Intended Commercial Formulation Of ART27.13 CI
08-17 Artelo Biosciences Receives Notice Of Allowance For U.S. Patent Covering Intended Commercial Formulation Of ART27.13 CI
08-12 Artelo Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-10 Artelo Biosciences, Inc. Enrolls First Patient in Phase 2 Clinical Trial Evaluating ART27.13 for Treatment of Glaucoma CI
07-16 Artelo Biosciences, Inc. Announces Results from Nonclinical Osteoarthritis Study Supporting ART26.12 as Potential First-In-Class New Therapy for Chronic Pain Conditions CI
07-16 Artelo Biosciences Says New Data Shows ART26.12 Reduces Osteoarthritis Pain MT
07-13 Artelo Says ART27.13 Decreases Neuropathic Pain-linked Behaviors in Animals Treated With Paclitaxel MT
07-13 Artelo Biosciences Announces Positive Results With ART27.13 In A Nonclinical Model Of Paclitaxel-Induced Peripheral Neuropathy CI
07-01 Artelo Biosciences Announces New Data Supporting ART26.12 As A Potential First-In-Class Therapy For Chronic Pain Associated With Spinal Cord Injury CI
1 day-9.69%
1 week-13.96%
Current month-13.96%
1 month-43.99%
3 months-70.57%
6 months-92.08%
Current year-94.20%
1 week 1.91
Extreme 1.91
2.42
1 month 1.91
Extreme 1.91
3.45
Current year 1.91
Extreme 1.91
179.19
1 year 1.91
Extreme 1.91
179.19
3 years 1.91
Extreme 1.91
772.2
5 years 1.91
Extreme 1.91
2,502.9
10 years 1.91
Extreme 1.91
52,487.93
Manager TitleAgeSince
Chief Executive Officer 63 2017-04-02
Director of Finance/CFO 67 2024-11-30
Chief Tech/Sci/R&D Officer - 2020-12-31
Director TitleAgeSince
Director/Board Member 63 2017-04-02
Chairman 72 2017-05-01
Director/Board Member 61 2017-05-01
Date Insider Type Main position Quantity % Market Cap. Importance
7/17/26 Free

Director

136 0.0039%
7/17/26 Free

Director

136 0.0039%
7/17/26 Free

Director

136 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
-9.69%-13.96%-96.76%-99.15% 1.05M
-4.83%+3.51%+55.00%+63.79% 66.7B
+0.02%+1.07%+11.72%+75.63% 56.88B
-1.34%+2.98%+25.08%+100.18% 56.53B
+5.09%+9.89%+27.19%+105.85% 46.49B
+2.62%+1.68%+29.16%+35.86% 44.8B
+8.24%+0.51%+215.16%+794.74% 41.59B
-1.86%+10.13%+28.14%+55.48% 35.35B
-2.97%-9.84%+90.91%+73.49% 33.29B
+5.19%+1.62%-39.69%+368.87% 25.1B
Average +0.05%+0.99%+34.59%+157.47% 40.67B
Weighted average by Cap. +0.65%+3.07%+49.90%+165.87%

Financials

2024 2025
Net sales - -
Net income -9.83M -8.81M -8.05M -7.35M -13.85M -924M -14.29M -97.08M -38.71M -493M -36.88M -36.09M -1.56B -12.88M -11.55M -10.56M -9.64M -18.16M -1.21B -18.73M -127M -50.74M -646M -48.34M -47.3M -2.04B
Net Debt -2.23M -2M -1.83M -1.67M -3.15M -210M -3.25M -22.07M -8.8M -112M -8.39M -8.21M -354M 78K 69.96K 63.94K 58.36K 110K 7.33M 113K 771K 307K 3.91M 293K 286K 12.35M
Projected Income Statement - Annual - Artelo Biosciences, Inc.
Logo Artelo Biosciences, Inc.
Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of therapeutics that modulate lipid-signaling pathways. The Company is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Its pipeline products include ART26.12, ART27.13 and ART12.11. ART26.12, its Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The Cancer Appetite Recovery Study (CAReS) is a Phase 1/2 randomized, placebo-controlled trial of its clinical program, ART27.13, in patients with cancer anorexia and weight loss. ART12.11, the Company's novel solid-state cannabidiol composition co-formed with tetramethylpyrazine, is targeted for development in anxiety disorders and rare/orphan diseases.
Employees
-
Date Price Change Volume
26-11-06 US$1.910 -9.69% 17,649
26-11-05 US$2.115 -6.83% 52,871
26-11-04 US$2.270 -5.42% 8,521
26-11-03 US$2.400 +10.60% 31,102
26-11-02 US$2.170 -2.25% 45,257

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Artelo Biosciences, Inc.
  1. Stock Market
  2. Stocks
  3. ARTL Stock